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Abstract
Progressive familial intrahepatic cholestasis (PFIC) refers to heterogeneous group of autosomal
recessive disorders of childhood that disrupt bile formation and present with cholestasis of
hepatocellular origin. The exact prevalence remains unknown, but the estimated incidence varies
between 1/50,000 and 1/100,000 births.
Three types of PFIC have been identified and related to mutations in hepatocellular transport
system genes involved in bile formation. PFIC1 and PFIC2 usually appear in the first months of life,
whereas onset of PFIC3 may also occur later in infancy, in childhood or even during young
adulthood. Main clinical manifestations include cholestasis, pruritus and jaundice. PFIC patients
usually develop fibrosis and end-stage liver disease before adulthood. Serum gamma-
glutamyltransferase (GGT) activity is normal in PFIC1 and PFIC2 patients, but is elevated in PFIC3
patients. Both PFIC1 and PFIC2 are caused by impaired bile salt secretion due respectively to
defects in ATP8B1 encoding the FIC1 protein, and in ABCB11 encoding the bile salt export pump
protein (BSEP). Defects in ABCB4, encoding the multi-drug resistant 3 protein (MDR3), impair
biliary phospholipid secretion resulting in PFIC3.
Diagnosis is based on clinical manifestations, liver ultrasonography, cholangiography and liver
histology, as well as on specific tests for excluding other causes of childhood cholestasis. MDR3 and
BSEP liver immunostaining, and analysis of biliary lipid composition should help to select PFIC
candidates in whom genotyping could be proposed to confirm the diagnosis. Antenatal diagnosis
can be proposed for affected families in which a mutation has been identified. Ursodeoxycholic acid
(UDCA) therapy should be initiated in all patients to prevent liver damage. In some PFIC1 or PFIC2
patients, biliary diversion can also relieve pruritus and slow disease progression. However, most
PFIC patients are ultimately candidates for liver transplantation. Monitoring of hepatocellular
carcinoma, especially in PFIC2 patients, should be offered from the first year of life. Hepatocyte
transplantation, gene therapy or specific targeted pharmacotherapy may represent alternative
treatments in the future.
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Disease name and synonyms
PFIC = Progressive familial intrahepatic cholestasis
PFIC1 = Progressive familial intrahepatic cholestasis type
1 = Byler disease = FIC1 deficiency
PFIC2 = Progressive familial intrahepatic cholestasis type
2 = Byler syndrome = BSEP deficiency
PFIC3 = Progressive familial intrahepatic cholestasis type
3 = MDR3 deficiency
Definition
Progressive familial intrahepatic cholestasis (PFIC) refers
to heterogeneous group of autosomal recessive liver disor-
ders of childhood in which cholestasis of hepatocellular
origin often presents in the neonatal period or first year of
life and leads to death from liver failure at ages usually
ranging from infancy to adolescence [1,2]. Recent molec-
ular and genetic studies have allowed the identification of
genes responsible for three types of PFIC and have shown
that they were related to mutations in hepatocellular
transport system genes involved in bile formation (Figure
1).
Epidemiology
In our experience, PFIC represents 10 to 15% of causes of
cholestasis in children and 10 to 15% of liver transplanta-
tion indications in children. PFIC1 and PFIC2 represent 2/
3 of cases of PFIC, and PFIC3 1/3 of cases [3]. The true
incidence of PFIC is not precisely known, but PFIC is con-
sidered a rare disease with an estimated incidence of 1/
50,000 to 1/100,000 births. All types of PFIC exist world-
wide. Both sexes seem to be equally affected.
Clinical description
Main characteristics of PFIC 1–3 are summarized in Table
1.
Cholestasis is a major clinical sign in all PFIC forms.
It usually appears in the first months of life in patients
with PFIC1, and is characterized by recurrent episodes of
jaundice, which become permanent later in the course of
the disease. In case of PFIC2, the initial presentation and
the evolution seem to be more severe, with permanent
jaundice from the first months of life and rapid appear-
ance of liver failure within the first years of life. Early
hepatocellular carcinoma (before one year of age) may
Progressive Familial Intrahepatic Cholestasis (PFIC): Types, related genes, and transport defects Figure 1
Progressive Familial Intrahepatic Cholestasis (PFIC): Types, related genes, and transport defects. BA: bile acid; 
PC: phosphatidylcholine.
FIC1
P type ATPase
BSEP
MDR3
Disease Gene Transport defect
Phosphatidyl serine
Phosphatidyl ethanolamine
Aminophospholipids
ATP8B1
18q 21-22
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BA PFIC2
ABCB4
7q 21
PFIC3
ABCB11
2q 24
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complicate the course of PFIC2. Severe pruritus is usually
observed in PFIC1 and PFIC2 patients. Phenotypic find-
ings in PFIC1 and PFIC2 are similar, but some slight phe-
notypic difference have been identified [1,4-8].
Extrahepatic features that have been reported in PFIC1
patients (persistent short stature, sensorineural deafness,
watery diarrhea, pancreatitis, elevated sweat electrolyte
concentration, liver steatosis) [9], have not been described
in PFIC2. In PFIC3, clinical signs of cholestasis are noted
within the first year of life in about one third of patients
and rarely in the neonatal period, in contrast to PFIC1 and
2. PFIC3 may also manifest later in infancy, in childhood
or even in young adulthood. Gastrointestinal bleeding
due to portal hypertension and cirrhosis is the presenting
symptom in adolescent or young adult patients. Pruritus
is usually mild. Evolution is characterized by chronic
icteric or anicteric cholestasis, portal hypertension and
liver failure. In half of the patient, liver transplantation is
required at a mean age of 7.5 years. No liver tumor has yet
been reported in association with PFIC3 [10].
Laboratory findings
Patients with PFIC1 and PFIC2 have normal serum
gamma-glutamyltransferase (GGT) activity, normal
serum cholesterol level and very high serum bile acid con-
centration. Although PFIC1 and PFIC2 share similar labo-
ratory findings, PFIC2 patients have higher transaminase
and alpha-fetoprotein serum levels at diagnosis than
those with PFIC1 [1,4-9]. Patients with PFIC3 have a per-
sistent high serum GGT activity, normal serum cholesterol
level and moderately raised concentrations of serum pri-
mary bile salts.
Histological findings
In PFIC1 patients, liver histology is characterized by canal-
icular cholestasis and the absence of true ductular prolif-
eration with only periportal biliary metaplasia of
hepatocytes. In PFIC2 patients, the same signs are seen but
the liver architecture is more perturbed, with more pro-
nounced lobular and portal fibrosis and inflammation.
Hepatocellular necrosis and giant cell transformation is
also much more pronounced in PFIC2 than in PFIC1 and
may persist with time. These differences between PFIC1
and PFIC2 likely reflect the severe lobular injury present
in PFIC2 (Figure 2A–B) [1,8,9].
In PFIC3, liver histology, obtained at the time of diagnosis
(Figure 2C), shows portal fibrosis and true ductular prolif-
Table 1: Main characteristics of Progressive Familial Intrahepatic Cholestasis (PFIC)
PFIC1
(Byler's disease)
PFIC2
(BSEP deficiency)
PFIC3
(MDR3 deficiency)
Transmission autosomal recessive autosomal recessive autosomal recessive
Pruritus severe severe moderate
Serum GGT activity normal normal high
Ductular proliferation absent absent present
Serum primary bile acid
concentration
very high very high high
Bile composition low
primary bile acid
concentration
very low
primary bile acid
concentration
low
phospholipid
concentration
Chromosomal locus 18q21-22 2q24 7q21
Gene/protein ATP8B1
FIC1
ABCB11
BSEP
ABCB4
MDR3
Hepatocyte location canalicular membrane canalicular membrane canalicular membrane
Other sites of expression Cholangiocytes
Intestine, Pancreas
none none
Functional defect ATP-dependent
aminophospholipid transport
ATP-dependent
bile acid transport
in bile
ATP-dependent phosphatidylcholine translocation in bileOrphanet Journal of Rare Diseases 2009, 4:1 http://www.ojrd.com/content/4/1/1
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Liver histology Figure 2
Liver histology. A: liver histology in a PFIC1 patient at age six months. It shows moderate lobular and portal fibrosis; B: liver 
histology in a PFIC2 patient at age 11 months. It shows hepatocellular necrosis, giant cell transformation and cirrhosis; C: liver 
histology in a PFIC3 patient at age 10 months. It shows strong (true) ductular proliferation within the all portal tract; D: at age 
5 years in the same PFIC3 patient, there is a typical picture of biliary cirrhosis with ductules containing bile plugs, while patent 
biliary tree.
A
B
C
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eration with mixed inflammatory infiltrate. In a few
instances, cholestasis is present in the lobule and in some
ductules containing bile plugs. Slight giant transforma-
tion of hepatocytes can be observed. Cytokeratin immu-
nostaining confirms the strong ductular proliferation
within the portal tract. At a later stage (Figure 2D), there is
extensive portal fibrosis and a typical picture of biliary cir-
rhosis. Interlobular bile ducts are seen in most portal
tracts and there is neither periductal fibrosis nor biliary
epithelium injury [11].
Etiology
PFIC 1
The first type, called PFIC1 (Byler disease) is caused by
mutations in the ATP8B1 gene (also designated FIC1)
[6,12]. This gene, which encodes a P-type ATPase, is
located on human chromosome 18 and is also mutated in
the milder phenotype, benign recurrent intrahepatic
cholestasis type 1 (BRIC1) and in Greenland familial
cholestasis [6,12,13]. FIC1 protein is located on the canal-
icular membrane of the hepatocyte but within the liver it
is mainly expressed in cholangiocytes [14-16]. The func-
tion of this P-type ATPase is unknown but it could be an
aminophospholipid transporter responsible for maintain-
ing the enrichment of phosphatidylserine and phosphati-
dylethanolamine on the inner leaflet of the plasma
membrane in comparison of the outer leaflet [6,14]. The
asymmetric distribution of lipids in the membrane bilayer
plays a protective role against high bile salt concentrations
in the canalicular lumen [17]. How mutations in this pro-
tein cause cholestasis is unclear. It is postulated that
abnormal protein function might indirectly disturb the
biliary secretion of bile acids, explaining the low biliary
bile acid concentration found in PFIC1 patients [4,6]. Dif-
ferent studies have shown that impaired ATP8B1 function
in patients with PFIC1 results in substantial down regula-
tion of FXR, a nuclear receptor involved in the regulation
of bile acid metabolism with subsequent downregulation
of BSEP in the liver and upregulation of bile acid synthe-
sis, and of the apical sodium bile salt transporter (ASBT)
in the intestine [16,18,19]. All in all, these events lead to
hepatocyte bile acid overload. Moreover, evidence for
cystic fibrosis transmembrane conductance regulator
(CFTR) down regulation in cholangiocytes has also been
reported in patients with PFIC1 which could contribute to
impairment of bile secretion and explain some extrahe-
patic features [16].
The ATP8B1 gene is expressed in various organs, including
the liver, pancreas, kidney and small intestine, but is more
highly expressed in the small intestine than in the liver
[12]. Therefore, it is thought to also be involved in the
enterohepatic cycling of bile salts. This may also explain
the chronic diarrhea present in a few children with PFIC1.
Other extrahepatic features associated with PFIC1 such as
persistent short stature, deafness and pancreatitis suggest
a general cell biological function for FIC1 [6,9,20].
It is very likely that FIC1 disease represents a continuum
with intermediate phenotypes between the benign pheno-
type BRIC1 and the severe phenotype PFIC1 [6]. So far,
there is no clear explanation for the phenotypic difference
between patients with BRIC1 and those with PFIC1. Muta-
tion analyses suggest that mutations identified in patients
with PFIC1 would severely disrupt protein function,
whereas protein function would be only partially
impaired in patients with BRIC1 [21]. Genotype-pheno-
type associations will probably be complicated because
dramatic variability in phenotypic presentation has
already been identified in patients with BRIC1 with a
common mutation. In addition, many patients with FIC1
disease are compound heterozygous, which will also com-
plicate the identification of genotype-phenotype correla-
tions [21]. Heterozygous ATP8B1  mutations have also
been identified in some cases of intrahepatic cholestasis
of pregnancy (ICP), that can be referred to under the term
ICP type 1 (ICP1) [22,23].
PFIC 2
The second type, called PFIC2, is caused by mutations in
the ABCB11 gene (also designated BSEP) [7,24]. Initially,
PFIC2 was reported under the name Byler syndrome [1,4].
The ABCB11 gene encodes the ATP-dependent canalicular
bile salt export pump (BSEP) of human liver and is
located on human chromosome 2. BSEP protein,
expressed at the hepatocyte canalicular membrane, is the
major exporter of primary bile acids against extreme con-
centration gradients. Mutations in this protein are respon-
sible for the decreased biliary bile salt secretion described
in affected patients, leading to decreased bile flow and
accumulation of bile salts inside the hepatocyte with
ongoing severe hepatocellular damage.
BSEP deficiency represents also a phenotypic continuum
between BRIC2 and PFIC2. So far, no clear genotype-phe-
notype correlation has been identified among PFIC2
patients, but most children with BSEP mutations, regard-
less of the mutation type, had no canalicular BSEP protein
expression [5]. Severe phenotypes are often associated
with mutations leading to premature protein truncation
or failure of protein production. Insertion, deletion, non
sense and splicing mutations result in damaging effects
and patients exhibited little or no detectable BSEP at the
hepatocyte canaliculus. Missense mutations are also com-
mon defects [25] that either affect protein processing and
trafficking (i.e.  p.E297G, p.D482G) [26,27] or disrupt
functional domains and protein structure. Thus detectable
BSEP expression (i.e.  p.N490D, p.G562D, p.R832C,
p.A1110E) does not exclude functional BSEP deficiency.Orphanet Journal of Rare Diseases 2009, 4:1 http://www.ojrd.com/content/4/1/1
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Some mutations have been functionally characterized
confirming the defect of bile acid secretion [28,29].
In milder disease, such as BRIC2 [30], missense mutations
predominate over those leading to failure of protein pro-
duction and mutations occur in less conserved regions
than in the NBFs (nucleotide binding fold) which contain
the Walker A/B motifs and ABC signature. Cholelithiasis
was also reported in BRIC2 patients [[30,31] and E. Jac-
quemin personal data]. Heterozygous ABCB11 mutations
have also been identified in cases of ICP (ICP2) [32], drug
induced cholestasis [33] and transient neonatal cholesta-
sis [34].
PFIC 3
The third type of PFIC, called PFIC3, is caused by a genetic
defect in the ABCB4 gene (also designated MDR3) located
on chromosome 7. Class III Multidrug Resistance (MDR3)
P-glycoprotein (P-gp), is a phospholipid translocator
involved in biliary phospholipid (phosphatidylcholine)
excretion and is predominantly, if not exclusively,
expressed in the canalicular membrane of the hepatocyte
[10]. Cholestasis results from the toxicity of bile in which
detergent bile salts are not inactivated by phospholipids,
leading to bile canaliculi and biliary epithelium injuries.
The mechanism of liver damage in PFIC3 patients is likely
related to the absence of biliary phospholipids [11].
Injury to bile canaliculi and biliary epithelium results
probably from continuous exposure to hydrophobic bile
salts, the detergent effects of which are no longer coun-
tered by phospholipids, leading to cholangitis [11]. In
addition, the stability of mixed micelles in bile is deter-
mined by a three-phase system, in which a proper propor-
tion of bile salts and phospholipids are necessary to
maintain solubility of cholesterol. The absence of phos-
pholipids in bile would be expected to destabilize
micelles and promote lithogenicity of bile with crystalliza-
tion of cholesterol, which could favor small bile duct
obstruction. These cholangiopathy mechanisms fit well
with the histologic findings such as ductular proliferation.
PFIC3 represents an important example of canalicular
transport defect that leads to the development of cholan-
giopathy.
The phenotypic spectrum of PFIC3 ranges from neonatal
cholestasis to cirrhosis in young adults [11,35]. In our
experience, ABCB4 sequence analysis in 50 PFIC3 patients
revealed around 30 different ABCB4  mutations. Muta-
tions were characterized on both alleles in most cases. In
one third of cases, mutations gave rise to a truncated pro-
tein. When tested, no MDR3 P-glycoprotein could be
detected by immunostaining in the liver of these patients.
The absence of MDR3 protein can be explained in two
ways. The truncated protein may be broken down very
rapidly after synthesis giving rise to extremely low steady
state levels of the protein. More likely, the premature stop
codon may lead to instability and decay of the ABCB4
mRNA. This latter explanation is supported by the near
absence of ABCB4 mRNA in northern blottings on liver
samples from several patients [36,37]. The remaining 2/3
of patients had missense mutations. Some of them were
found in the highly conserved aminoacids sequences of
the Walker A and B motifs which are involved in ATP-
binding [38]. Such aminoacid changes in the Walker A or
B motif are generally not compatible with ATPase activity
and transport processes [38-41]. Alternatively, missense
mutations might result in intracellular misprocessing of
MDR3 as shown for other ABC transporters [27,42-44].
Indeed, such missense mutations were associated with a
decreased level of MDR3 canalicular protein [44]. What-
ever the mechanism involved, the low level of biliary
phospholipids found in patients with missense mutations
demonstrates the MDR3 functional defect [11]. There is
now strong evidence that in addition to PFIC3, an MDR3
defect can be involved in ICP (ICP3) [32,43,45-48], cho-
lesterol gallstone disease [49-52] and drug induced
cholestasis [53-55]. A MDR3 defect is also likely to be
involved in some cases of transient neonatal cholestasis
and adult idiopathic cirrhosis [10,35,56]. MDR3 defi-
ciency may also represent a clinical continuum, as a single
patient may experience different phenotypes during the
disease course, starting with cholesterol cholelithiasis,
then ICP and ending with biliary cirrhosis [57].
Diagnosis and diagnostic methods
PFIC should be suspected in children with a clinical his-
tory of cholestasis of unknown origin after exclusion of
other main causes of cholestasis, (e.g.  biliary atresia,
Alagille syndrome, alpha1antitrypsine deficiency, cystic
fibrosis, sclerosing cholangitis and extrahepatic bile duct
obstruction) [11]. High serum bile acid concentration
excludes primary disorders of bile acid synthesis [58].
Patients with PFIC1 and PFIC2 have normal serum GGT
activity, while patients with PFIC3 have high serum GGT
activity. PFIC3 patients can also be distinguished from
patients with the other types of PFIC (PFIC1 and PFIC2)
in that they present rarely with cholestatic jaundice at the
neonatal period, but rather later in infancy, in childhood
or in young adulthood. A schematic approach to the diag-
nosis of PFIC is proposed in Figure 3. This combined clin-
ical, biochemical, radiological and histological approach
associated with liver immunostaining and biliary lipid
analysis, should help to select PFIC candidates in whom a
molecular diagnosis can be proposed.
Diagnostic methods
• Radiological approach
Initial ultrasonography of the liver is performed to
exclude biliary tract disease. Typically, ultrasonography is
normal but may reveal a huge gallbladder. Sometimes,Orphanet Journal of Rare Diseases 2009, 4:1 http://www.ojrd.com/content/4/1/1
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biliary stones may be identified. When performed,
cholangiography shows a normal biliary tree, excluding
sclerosing cholangitis, and allows bile to be collected for
biliary lipid analysis [11].
• Liver histology
is important for diagnosis. It also allows liver immunos-
taining to be performed. Typical features were described
in the clinical description section and are shown in Figure
2. When signs of biliary obstruction are seen at liver
biopsy, as may occur in PFIC3, cholangiography must be
performed to exclude sclerosing cholangitis [11,59].
• Liver immunostaining
Commercially available MDR3 and BSEP antibodies
allow liver immunostaining to be performed [5,11,25].
Absence of canalicular or mild immunostaining are in
favor of a gene defect. Normal staining does not exclude a
gene defect as a mutation may induce a loss of function
but normal synthesis and addressing.
• Electron microscopy
Typical ultrastructural aspects of bile may allow differen-
tiation of PFIC1 and PFIC2 but liver ultrastructural histol-
ogy is not easily available [4,60].
• Biliary lipid analysis
Biliary lipid analysis is performed on gallbladder bile or
on bile collected by duodenal aspiration (pure choledo-
chal bile). In case of gallbladder punction, bile contami-
nation by blood may falsify bile analysis. In case of
duodenal aspiration, bile dilution or bile contamination
by alimentary phospholipids may falsify bile analysis. The
biliary bile salt concentration is dramatically decreased
(<1 mM) in PFIC2 patients [5] and only mildly decreased
in PFIC1 patients (3–8 mM) [[9] and A. Davit-Spraul, per-
sonal data]. The normal concentration of biliary primary
bile salts distinguishes PFIC3 patients from those with
PFIC1 and PFIC2 [4,5,11,58]. In PFIC3 patients, the bil-
iary phospholipid level is dramatically decreased (1–15%
of total biliary lipids; normal range 19–24%). Biliary bile
salt:phospholipid and cholesterol:phospholipid ratios are
approximately 5-fold higher than in wild type bile. The
residual percentage of biliary phospholipids seems
Schematic approach to the diagnosis of PFIC excluding the neonatal period, during which biliary atresia is the main cause of  cholestasis Figure 3
Schematic approach to the diagnosis of PFIC excluding the neonatal period, during which biliary atresia is the 
main cause of cholestasis.
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directly related to the severity of MDR3 mutation and con-
sequently to the residual activity of the MDR3 P-glycopro-
tein. Patients with "severe" mutations (nonsense,
frameshift) have a low percentage of biliary phospholip-
ids <2%, while patients with missense mutations have a
high percentage of biliary phospholipids ≥ 2%. In our
experience, the threshold that predicts a positive response
to ursodeoxycholic acid (UDCA) therapy in PFIC3, is rep-
resented by a percentage of biliary phospholipids of
around 7%. The combination of abnormal MDR3 canal-
icular immunostaining and low percentage of biliary
phospholipids is highly suggestive of MDR3 deficiency.
• Molecular analysis
PFIC1: ATP8B1 gene (coding exons 2–28)
PFIC2: ABCB11 gene (coding exons 2–28)
PFIC3: ABCB4 gene (coding exons 2–28)
Gene analysis is usually performed by DNA sequencing of
the 27 coding exons and their splice junctions. In case of
silent or intronic mutations, a in silico test is helpful to pre-
dict a potential splice defect which must be confirmed by
RNA analysis (RT-PCR and sequencing) [61]. The use of a
resequensing chip dedicated to genetic cholestasis could
facilitate identification of gene mutation [62].
• 31P MRS spectroscopy
It remains to be evaluated if 31P MRS (Magnetic Reso-
nance Spectroscopy) would be a valuable non-invasive
tool to characterize canalicular transport defects, such as
was suggested for ICP1 [22].
Differential diagnosis
Several other autosomal recessive PFIC-like diseases are
known. Liver diseases resembling PFIC with normal GGT
activity have been identified as inborn errors in primary
bile acid synthesis and represent distinct disorders [58].
Other liver diseases resembling PFIC with normal serum
GGT activity are recognized. Familial Amish hyper-
cholanemia represents a PFIC-like disorder not due to a
primary defect of the transport system involved in bile for-
mation, but to a tight junction protein defect combined
with a defect of primary bile acid conjugation [63,64].
Cholestasis is due to impaired transport of unconjugated
bile acids into bile and to bile leakage into plasma
through abnormal canalicular tight junctions increasing
paracellular permeability. Another category of progressive
cholestastic liver disease of childhood could be due to
abnormal villin expression, leading to loss of structural
integrity of canalicular microvilli impairing biliary secre-
tion system function [65]. A case of hypercholanemia due
to mutations in the m-epoxide hydrolase gene has also
been reported (EPHX1) [66,67]. Arthrogryposis-renal dys-
function cholestasis syndrome is a complex disease due to
mutation of VPS33B involved in intracellular trafficking
and targeting of apical proteins. The gene defect results in
a loss of apical protein expression in the liver and kidneys
[68]. From a liver point of view, it represents another
PFIC-like disorder with normal GGT activity. In cases of
high serum GGT activity, sclerosing cholangitis must be
excluded [59,69]. North American Indian Childhood Cir-
rhosis due to a defect in the cirrhin gene is characterized
by high GGT activity [70] as is Aagenes syndrome, a
lymphedema cholestasis syndrome of unknown cause
[71].
Genetic counseling and antenatal diagnosis
Genotyping should be used to confirm the diagnosis of
PFIC in affected children. Heterozygosity of parents for
the defects found in affected patients confirmed the reces-
sive inheritance of the disease. This understanding has
already allowed prenatal diagnosis. Antenatal diagnosis of
PFIC requires clinical and biochemical expertise [56].
Specific management including treatment
Therapy with UDCA should be considered in the initial
therapeutic management of children with all types of
PFIC [72]. UDCA therapy may be effective in some
patients, especially those with PFIC3 with missense muta-
tions who have less severe disease in comparison to chil-
dren with a mutation leading to a truncated protein [11].
Some patients with PFIC1 or PFIC2 may also benefit from
surgical biliary diversion [73,74]. Nasobiliary drainage
may help to select potential responders to biliary diver-
sion [75]. So far, clear genotype-phenotype correlation
data are missing and remain to be defined in order to
identify those PFIC1-2 patients who could benefit from
UDCA or biliary diversion [3,60]. Preliminary data sug-
gest that PFIC2 patients with p.D482G or p.E297G muta-
tions may respond well to biliary diversion [60].
If these therapies fail, liver transplantation represents the
only alternative [76]. In our experience, extrahepatic fea-
tures, such as diarrhea, liver steatosis and short stature
sometimes associated with PFIC1, do not improve or may
be aggravated after successful biliary diversion or liver
transplantation [9]. Chronic diarrhea may become intrac-
table when biliary bile salt secretion is restored after liver
transplantation [6,9,20]. It is often associated with severe
liver steatosis and/or steatohepatitis that may lead to cir-
rhosis with time and to indication to retransplantation.
Liver steatosis and diarrhea may recur after retransplanta-
tion (E. Jacquemin, personal data). Diarrhea might be
favorably managed by bile adsorptive resin treatment
[9,20].Orphanet Journal of Rare Diseases 2009, 4:1 http://www.ojrd.com/content/4/1/1
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In the future, therapies such as cell, gene or specific tar-
geted pharmacological therapies (i.e. FXR inducers, chap-
erone drugs), might represent an alternative therapy for
all types of PFIC [27,60,77-79]. In PFIC2, it is uncertain
whether hepatocyte transplantation or gene therapy with
modified hepatocytes represents a good therapeutic
approach. Indeed, with this approach, it may be a risk to
leave premalignant liver cells in place, especially in
patients with severe biallelic ABCB11 mutations [80].
Prognosis
In addition to the natural history and complications of
PFIC1-3 (portal hypertension, liver failure, cirrhosis,
hepatocellular carcinoma, extrahepatic manifestations),
children with PFIC1-3 are theoretically at risk of develop-
ing further in the disease course, biliary stones, drug-
induced cholestasis and ICP. Girls under UDCA therapy
who reach adulthood with their native liver must not stop
UDCA during pregnancy because of the risk of developing
severe ICP as seen in a previously reported patient [53]
who became pregnant (personal data Dr N. Ganne-Carrié,
Hepatology Unit, Jean Verdier Hospital, Bondy, France).
Patients with BSEP deficiency, especially those with bial-
lelic truncating mutations, are at considerable risk for
hepatobiliary malignancy (15% may develop hepatocel-
lular carcinoma or cholangiocarcinoma) [[25,80] and E.
Jacquemin personal data]. These findings justify close
monitoring of hepatocellular carcinoma (At least, serum
alpha fetoprotein dosage every 6 months and liver ultra-
sonography every year) in PFIC2 patients from the first
year of life.
Unresolved questions
In very rare PFIC patients (< 10%), only one mutated
allele or no mutation is identified. This can be explained
by mutations that may map to regulatory sequences of the
genes. A gene involved in the transcription of PFIC genes
(i.e. FXR) or in protein trafficking could also be involved
[81,82]. It is also possible that other unidentified genes
involved in bile formation may be responsible for the
PFIC1-3 phenotypes. Furthermore, it may be hypothe-
sized that combined heterozygous mutations for two
genes (i.e. MDR3 and BSEP) lead to PFIC like phenotype
[49]. An interesting possibility is also that in a hetero-
zygous state, the mutated protein may have a dominant
negative effect on protein expression/function [83]. Mod-
ifier genes and environmental influences could play a role
in the expression of PFIC [58].
After liver transplantation the possible "recurrence of
PFIC" on liver grafts due to alloimmunization of the
recipient against the BSEP, MDR3 or FIC1 proteins of liver
donor remains a theoretical matter of debate. It is hypoth-
esized that PFIC patients with a severe mutation leading
to absence of the gene product would be immunologically
naive for the FIC1, BSEP or MDR3 gene products. In this
context, alloimmunization could occur after liver trans-
plantation. To our knowledge, this complication has not
been reported so far after liver transplantation [76,84] but
we have observed a case of an PFIC2 male patient who
experienced an unexplained severe bout of pure hepato-
cellular cholestasis resembling PFIC2 after cadaveric liver
transplantation (E. Jacquemin, personal data). In addi-
tion, in case of parental living donor transplantation, it
could be expected that the heterozygous status of the liver
graft leads to a predisposition for developing lithiasis or
cholestasis favored by immunosuppressive drugs [33] that
may interfere with canalicular protein function, as we
have seen in a PFIC2 patient (E. Jacquemin, personal
data). Nevertheless, this complication is likely to be very
rare, since it has not been reported in a broad series of liv-
ing donor transplantation for PFIC [84].
Experimental perspectives
As already mentioned above, studies performed in cell
lines have determined the effects of some PFIC gene muta-
tions (ATP8B1  [17-19],  ABCB11  [26,28,29],  ABCB4
[41,43,44]). This should allow testing of some drugs that
may restore, at least partially, the function or the targeting
of a mutated protein [27,78,79]. Besides these cell studies,
mouse models of PFIC1-3 have been created by genetic
engineering [85-87]. Mainly, the PFIC1-2 models have
demonstrated that the phenotypes of the mice were much
less severe than in humans. Although the phenotypes
were aggravated by supplementation with cholic acid, the
main bile salt in humans, this was not sufficient to induce
liver injury comparable to that seen in PFIC1-2 patients.
The likely reason for this is that mice, unlike humans, may
easily detoxify hydrophobic bile salts by hydroxylation,
via the cytochrome P450 enzyme system, resulting in a
less cytotoxic bile salt pool. Therefore, it would be inter-
esting to generate new mouse models that closely resem-
ble PFIC1-2. Recently, cytochrome P450 knockout mice
have been generated [88]. It is expected that crossing PFIC
mouse models with mice with a disrupted liver cyto-
chrome P450 oxidoreductase gene will generate mice sen-
sitive to human bile salts. Such new mouse models could
develop liver diseases that closely reproduce PFICs and
will allow better experimental studies of the pathophysi-
ology of PFICs and test the effects of treatments.
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